Completed

Myo-inositol vs Metformin for Obesity Treatment in PCOS Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to compare the effectiveness of Myo-inositol and Metformin in reducing body mass index as a treatment for obesity in patients with Polycystic Ovary Syndrome (PCOS).

What is being tested

Myo-inositol

+ Metformin

Drug
Who is being recruted

Urogenital Diseases+10

+ Genital Diseases

+ Adnexal Diseases

From 18 to 45 Years
+4 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: November 2024
See protocol details

Summary

Principal SponsorMuhammad Aamir Latif
Last updated: February 5, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 29, 2024

Actual date on which the first participant was enrolled.

This study focuses on comparing two treatments, myo-inositol and metformin, for managing obesity in patients with Polycystic Ovarian Syndrome (PCOS). The aim is to understand which treatment works better and is more tolerable for these patients. PCOS is a common health condition that can lead to obesity and other metabolic disorders. This research is important as it can help gynecologists make more informed decisions when choosing medications for their patients, potentially improving their quality of life and reducing psychological impacts associated with obesity, such as discrimination and low self-esteem. During the study, participants receive either myo-inositol or metformin as their treatment. The main goal is to measure the reduction in body mass index (BMI) from the start of the study. This helps determine the effectiveness of each treatment. The study also considers the side effects of each medication to understand which one is more tolerable for patients with PCOS.

Official TitleComparison of Myo-inositol Versus Metformin for Treating Obesity in Patients With Polycystic Ovarian Syndrome
NCT07387679
Principal SponsorMuhammad Aamir Latif
Last updated: February 5, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

60 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 45 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesCystsEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGonadal DisordersNeoplasmsOvarian CystsOvarian DiseasesPolycystic Ovary SyndromeFemale Urogenital Diseases

Criteria

2 inclusion criteria required to participate
Females aged 18-45 years
Diagnosed case of PCOS for more than 6 months of duration
2 exclusion criteria prevent from participating
Women with hyperprolactinemia or hypothyroidism (on history & medical record review)
Adrenal hyperplasia or Cushing's syndrome (on history & medical record review)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Women were given tablet myo-inositol 1 gm twice a day for 3 months.

Group II

Experimental
Women received metformin 250 mg three times daily for 3 months.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Bahwal Victoria Hospital

Bahawalpur, PakistanOpen Bahwal Victoria Hospital in Google Maps
CompletedOne Study Center